IGS1 Stock Overview A clinical stage pharmaceutical company, engages in developing treatments for Alzheimer’s disease. More details
Rewards Risk Analysis + 3 more risks
See All Risk Checks Capture your thoughts, links and company narrative
IGC Pharma, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for IGC Pharma Historical stock prices Current Share Price US$0.34 52 Week High US$0.69 52 Week Low US$0.23 Beta 1.31 1 Month Change 2.41% 3 Month Change 11.84% 1 Year Change 30.77% 3 Year Change -61.54% 5 Year Change -38.91% Change since IPO -96.83%
Recent News & Updates
IGC Pharma, Inc. Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology Dec 03
IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment Nov 26
Second quarter 2025 earnings released: US$0.023 loss per share (vs US$0.045 loss in 2Q 2024) Nov 14
IGC Pharma, Inc. Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1 Oct 17
Independent Director recently bought €179k worth of stock Sep 29
IGC Pharma, Inc. Advances IGC-AD1 Toward Clinical Trials as a Potential Anti-Amyloid Plaque Treatment for Alzheimer's Disease Sep 05 See more updates
IGC Pharma, Inc. Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology Dec 03
IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment Nov 26
Second quarter 2025 earnings released: US$0.023 loss per share (vs US$0.045 loss in 2Q 2024) Nov 14
IGC Pharma, Inc. Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1 Oct 17
Independent Director recently bought €179k worth of stock Sep 29
IGC Pharma, Inc. Advances IGC-AD1 Toward Clinical Trials as a Potential Anti-Amyloid Plaque Treatment for Alzheimer's Disease Sep 05
IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease Aug 22
IGC Pharma, Inc. Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist Aug 21
First quarter 2025 earnings released: US$0.033 loss per share (vs US$0.039 loss in 1Q 2024) Aug 09
IGC Pharma, Inc., Annual General Meeting, Aug 23, 2024 Jul 11
IGC Pharma's Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile Jul 10
IGC Pharma, Inc., Annual General Meeting, Aug 23, 2024 Jul 09
Full year 2024 earnings released: US$0.22 loss per share (vs US$0.22 loss in FY 2023) Jun 26
IGC Pharma, Inc.'S TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, A Key Hallmark of Alzheimer's Disease Jun 25
IGC Pharma, Inc. Announces Patient Enrollment At Neurostudies in Phase 2 Trial Investigating IGC-AD1 May 29
IGC Pharma, Inc Announces Interim Data from Its Phase 2 Clinical Trial Demonstrates Clinically Significant Reduction, Approaching Statistical Significance, in Agitation in Alzheimer’S At Week Two Compared to Placebo Apr 16 IGC Pharma, Inc. announced that it expects to receive $3 million in funding from Bradbury Asset Management (Hong Kong) Limited Mar 27
IGC Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $6.24051 million. Mar 22
Igc Pharma, Inc. Appoints Terry Lierman as Independent Director to Its Board of Directors Mar 13
Third quarter 2024 earnings released: US$0.088 loss per share (vs US$0.042 loss in 3Q 2023) Feb 16 IGC Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $5.309602 million.
Igc Pharma, Inc. Activates Clincloud, One of 12 Sites in Ongoing Phase 2B Alzheimer’S Trial Jan 17
Second quarter 2024 earnings released: US$0.045 loss per share (vs US$0.047 loss in 2Q 2023) Nov 12
IGC Pharma Expands Phase 2 Trial of IGC-Ad1 to Include the University of Puerto Rico Aug 03
IGC Pharma, Inc. Presents 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer's Association International Conference Jul 21 IGC Pharma, Inc. announced that it expects to receive $3 million in funding from Bradbury Asset Management (Hong Kong) Limited and other investors Jul 07
IGC Pharma, Inc. announced delayed annual 10-K filing Jul 01
Third quarter 2023 earnings released: US$0.042 loss per share (vs US$0.047 loss in 3Q 2022) Feb 16
India Globalization Capital, Inc. Receives No Objection Letter from Health Canada Jan 05
India Globalization Capital, Inc. Announces Board Changes Dec 30
India Globalization Capital, Inc. Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer’s Disease Dec 03
Second quarter 2023 earnings released: US$0.047 loss per share (vs US$0.087 loss in 2Q 2022) Nov 03
First quarter 2023 earnings released: US$0.054 loss per share (vs US$0.037 loss in 1Q 2022) Aug 07
India Globalization Capital, Inc., Annual General Meeting, Sep 09, 2022 Jul 26
Full year 2022 earnings released: US$0.30 loss per share (vs US$0.21 loss in FY 2021) Jun 24
India Globalization Capital, Inc. Receives U.S. Patent for Method and Composition for Treating Seizure Disorders Jun 09
India Globalization Capital, Inc. Announces Final Approval of Settlement of Shareholder Class Action Lawsuits Apr 19
The Rosen Law Firm, P.A. and Pomerantz LLP Announce Proposed Securities Class Action Settlement on Behalf of Purchasers of India Globalization Capital, Inc. Common Stock Feb 22
Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint Feb 11
The Rosen Law Firm, P.A. and Pomerantz LLP Announce Proposed Securities Class Action Settlement on Behalf of Purchasers of India Globalization Capital, Inc. Common Stock Jan 18
India Globalization Capital, Inc. Announces Positive Primary Endpoint Data for Its Phase 1 Clinical Trial for IGC-AD1 Dec 15
India Globalization Capital, Inc. Announces Preliminary Results for its Exploratory Endpoints from its Phase 1 IGC-AD1 Clinical Trial Dec 09
India Globalization Capital, Inc. to Present Preliminary Positive Secondary End Point Findings from its Phase 1 Clinical Trial for IGC-AD1 Dec 03
Second quarter 2022 earnings released: US$0.087 loss per share (vs US$0.04 loss in 2Q 2021) Oct 30
India Globalization Capital, Inc. Completes Its Phase 1 Clinical Trial on Alzheimer’s Patients, Reports Safety and Tolerability Sep 08
First quarter 2022 earnings released: US$0.037 loss per share (vs US$0.047 loss in 1Q 2021) Aug 13
India Globalization Capital, Inc Announces Issuance of Patent for the Treatment of Alzheimer’S Disease Using THC Jul 24
India Globalization Capital, Inc. Completes the Final Cohort of its Phase 1 Clinical Trial on Alzheimer’s Patients Jun 25
Full year 2021 earnings released: US$0.21 loss per share (vs US$0.18 loss in FY 2020) Jun 18
IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients Jun 08
India Globalization Capital, Inc. Completes Cohort 1 of Its Phase 1 Thc-Based Clinical Trial on Alzheimer’S Patients May 15
Independent Chairman of the Board recently sold €75k worth of stock Mar 10
India Globalization Capital, Inc. Provides Update on Phase 1 Clinical Trial on Alzheimer’S Patients Feb 24
Third quarter 2021 earnings released: US$0.056 loss per share (vs US$0.041 loss in 3Q 2020) Feb 14
New 90-day high: €2.09 Feb 13
India Globalization Capital, Inc. Approves the Election of John E. Lynch to the Board of Directors Jan 14
India Globalization Capital, Inc., Annual General Meeting, Jan 11, 2021 Dec 10
India Globalization Capital, Inc. Commences Phase 1 of Cannabinoid Clinical Trial for Alzheimer’S Patients Nov 25
India Globalization Capital, Inc. announced delayed 10-Q filing Nov 14
India Globalization Capital, Inc. announced delayed 10-Q filing Aug 15
India Globalization Capital, Inc.(AMEX:IGC) dropped from Russell Microcap Index Jul 03
India Globalization Capital, Inc. announced delayed annual 10-K filing Jun 30 Shareholder Returns IGS1 DE Pharmaceuticals DE Market 7D -2.3% 1.4% 0.5% 1Y 30.8% -16.3% 7.2%
See full shareholder returns
Return vs Market: IGS1 exceeded the German Market which returned 7% over the past year.
Price Volatility Is IGS1's price volatile compared to industry and market? IGS1 volatility IGS1 Average Weekly Movement 10.4% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: IGS1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: IGS1's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer’s disease. The company’s lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer’s; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023.
Show more IGC Pharma, Inc. Fundamentals Summary How do IGC Pharma's earnings and revenue compare to its market cap? IGS1 fundamental statistics Market cap €27.34m Earnings (TTM ) -€12.05m Revenue (TTM ) €1.13m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) IGS1 income statement (TTM ) Revenue US$1.18m Cost of Revenue US$518.00k Gross Profit US$665.00k Other Expenses US$13.23m Earnings -US$12.57m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.16 Gross Margin 56.21% Net Profit Margin -1,062.47% Debt/Equity Ratio 1.8%
How did IGS1 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/27 01:06 End of Day Share Price 2024/12/27 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources IGC Pharma, Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Molloy Alliance Global Partners Edward Woo Ascendiant Capital Markets LLC Aditya Khandekar RedChip Companies, Inc.
Show 2 more analysts 
